Alpha Score of 63 reflects moderate overall profile with strong momentum, strong value, weak quality, moderate sentiment.
| Date | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| Mar 17, 26 | Sabag Mark | See "Remarks" | SELL | 62.1K | $1.9M |
| Mar 5, 26 | Jover Placid | See "Remarks" | SELL | 14.2K | $448K |
| Mar 5, 26 | Francis Richard D | President and CEO | SELL | 20.0K | $634K |
| Mar 5, 26 | Fox Christine | EVP, U.S. Commercial | SELL | 7.9K | $251K |
| Mar 5, 26 | Hughes Eric A | See "Remarks" | SELL | 9.5K | $302K |
| Mar 5, 26 | Daniell Richard | EVP, Europe Commercial | SELL | 17.3K | $548K |
| Mar 5, 26 | Savage Brian | Interim Chief Legal Officer | SELL | 1.1K | $36K |
| Fund | Shares Held | Position Value | Action (latest Q) |
|---|---|---|---|
| Citadel Ken Griffin | 8.09M | $252.51M | NEW |
| D.E. Shaw David Shaw | 819K | $25.55M | NEW |
| Blackstone | 137K | $4.28M | NEW |
| ARK Invest Cathie Wood | 105K | $3.28M | NEW |
| Greenlight Capital David Einhorn | 268K | $2.80M | NEW |
| Marshall Wace | 27K | $830.2K | NEW |
| Point72 Steve Cohen | 7K | $212.2K | NEW |
| Duquesne Family Office Stanley Druckenmiller | 5.87M | $183.4K | NEW |
Teva Pharmaceutical Industries Ltd. ADR is an American Depositary Receipt representing shares of the Israel-based pharmaceutical company Teva Pharmaceutical Industries Ltd., founded in 1901 and headquartered in Tel Aviv, Israel. The company develops, manufactures, markets, and distributes a broad portfolio of generic medicines and innovative biopharmaceutical products across the United States, Europe, Israel, and international markets. Its generic offerings span various dosage forms including tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, creams, sterile products, hormones, high-potency drugs, and cytotoxics, often combined with medical devices. Teva specializes in key therapeutic areas such as the central nervous system with products like COPAXONE for multiple sclerosis, AJOVY for migraine prevention, and AUSTEDO for movement disorders; respiratory treatments including ProAir RespiClick, QVAR RediHaler, and DuoResp Spiromax; and oncology with biosimilars like Truxima and Herzuma, plus BENDEKA and TREANDA injections. Additionally, it supplies active pharmaceutical ingredients, provides contract manufacturing services, and operates a U.S.-based generic and specialty drug distribution platform through Anda. Teva's diverse operations position it as a leading global player in accessible healthcare solutions, serving patients with both cost-effective generics and specialized therapies.
Earnings calendar coming soon. Subscribe to get notified when TEVA reports next.
Get earnings alerts →